Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses
about
New Insights into the Generation of CD4 Memory May Shape Future Vaccine Strategies for InfluenzaSafety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adultsPlant-produced candidate countermeasures against emerging and reemerging infections and bioterror agentsOriginal Antigenic Sin Response to RNA Viruses and Antiviral ImmunityThe genome landscape of the african green monkey kidney-derived vero cell lineSerial Vaccination and the Antigenic Distance Hypothesis: Effects on Influenza Vaccine Effectiveness During A(H3N2) Epidemics in Canada, 2010-2011 to 2014-2015.Influenza vaccine effectiveness assessment through sentinel virological data in three post-pandemic seasons.A paradigm shift in vaccine production for pandemic influenza.Development of high-yield influenza A virus vaccine virusesDeep Sequencing Reveals Potential Antigenic Variants at Low Frequencies in Influenza A Virus-Infected Humans.Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza A(H1N1) Virus Differed by Vaccine Type During 2013-2014 in the United States.Effect of Statin Use on Influenza Vaccine Effectiveness.Novel Sequence-Based Mapping of Recently Emerging H5NX Influenza Viruses Reveals Pandemic Vaccine Candidates.Determination of antigenicity-altering patches on the major surface protein of human influenza A/H3N2 virusesEffects of egg-adaptation on receptor-binding and antigenic properties of recent influenza A (H3N2) vaccine viruses.Recent H3N2 influenza virus clinical isolates rapidly acquire hemagglutinin or neuraminidase mutations when propagated for antigenic analysesImpact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons.Influenza vaccine effectiveness in preventing influenza A(H3N2)-related hospitalizations in adults targeted for vaccination by type of vaccine: a hospital-based test-negative study, 2011-2012 A(H3N2) predominant influenza season, Valencia, Spain.Guidance for practitioners on the use of antiviral drugs to control influenza outbreaks in long-term care facilities in Canada, 2014-2015 season.Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus typeEffective and lesion-free cutaneous influenza vaccinationDoes Influenza Vaccination Modify Influenza Severity? Data on Older Adults Hospitalized With Influenza During the 2012-2013 Season in the United States.Mid-Season Estimates of Influenza Vaccine Effectiveness against Influenza A(H3N2) Hospitalization in the Elderly in Quebec, Canada, January 2015Effectiveness of Trivalent Inactivated Influenza Vaccine in Children Estimated by a Test-Negative Case-Control Design Study Based on Influenza Rapid Diagnostic Test Results.Generation and Characterization of Live Attenuated Influenza A(H7N9) Candidate Vaccine Virus Based on Russian Donor of Attenuation.The development and manufacture of influenza vaccines.Influenza vaccine effectiveness in preventing inpatient and outpatient cases in a season dominated by vaccine-matched influenza B virus.Detailed Report on 2014/15 Influenza Virus Characteristics, and Estimates on Influenza Virus Vaccine Effectiveness from Austria's Sentinel Physician Surveillance Network.Development of an Influenza A Master Virus for Generating High-Growth Reassortants for A/Anhui/1/2013(H7N9) Vaccine Production in Qualified MDCK Cells.H3N2 Mismatch of 2014-15 Northern Hemisphere Influenza Vaccines and Head-to-head Comparison between Human and Ferret Antisera derived Antigenic MapsThe effective rate of influenza reassortment is limited during human infectionPhylogenetic relationships of the HA and NA genes between vaccine and seasonal influenza A(H3N2) strains in KoreaPersistence of Antibodies to Influenza Hemagglutinin and Neuraminidase Following One or Two Years of Influenza Vaccination.Strategies for Early Vaccination During Novel Influenza Outbreaks.Illness Severity and Work Productivity Loss Among Working Adults With Medically Attended Acute Respiratory Illnesses: US Influenza Vaccine Effectiveness Network 2012-2013Phase 1 Safety and Immunogenicity Study of a Quadrivalent Seasonal Flu Vaccine Comprising Recombinant Hemagglutinin-Flagellin Fusion Proteins.Implementation of new approaches for generating conventional reassortants for live attenuated influenza vaccine based on Russian master donor viruses.Propagation and Characterization of Influenza Virus Stocks That Lack High Levels of Defective Viral Genomes and Hemagglutinin MutationsA Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-2015 SeasonAntigenic characterization of influenza viruses produced using synthetic DNA and novel backbones.
P2860
Q26752546-4712144C-FE54-4B71-B355-D576B3A53398Q26781949-6583271E-0A83-45A9-B87B-699298CDD142Q26783107-5DA6A63C-3CBC-4D1F-838F-23587AF8EB3FQ28066918-2B7A49BA-44AE-4717-ACAA-9773952627E8Q28649974-B2F476FD-8B4F-4779-88A9-74EBB8B92092Q30151372-425BB66F-F719-48B3-A97C-6D95337D7F4DQ30369475-A1FECF6C-9375-4236-8935-E92D99D5A0ACQ30377766-E5F61FF5-3FA7-4B4F-813D-786814CA05AEQ30378710-AC2A211E-E553-4533-BC40-4BD0DF9406F3Q30383252-9FB92380-163B-460D-9421-1041FB93E676Q30383312-E9D25B43-F338-4370-8317-BF0206DCE7F3Q30391150-B7F0EB91-417B-4444-85A6-A80D734F590FQ30391540-ECC601A1-FA20-4523-825A-DCE27721EA7AQ30394447-85DEC7A9-A895-466C-A58F-F4C242E116BFQ33573489-D6AFC19D-691B-4D4C-BA0C-7C21ABF7417AQ34262280-B4EAA3CD-B8CD-46A3-A15A-8A22BC261388Q34393525-C0E714DD-A964-481E-B1EF-E22D830DD4A2Q34505958-BE307E01-07A1-4A1B-A5AA-3953321E3E00Q35158142-E2415D87-14CA-4483-97FC-4A4AB6E775C2Q35531934-B9A6B90B-348E-4980-9DFC-31D8B061A713Q35549338-EC32FBBE-C176-49B1-9256-8640CECD05B6Q35589650-F494C1DB-8979-48E0-AEA6-0BFE0F43EAB0Q35705382-C1150722-8F74-4BF0-9328-17AB4F8FBD6FQ35758531-EED8D230-1546-4EA3-ACF8-82C54200999FQ35787563-6005EA55-E565-4A97-8244-9D2D7969A8A5Q35887123-8C09D7F7-1126-4AC1-93DD-F8CA2366B4F8Q35887612-C99C7220-FD5B-49BD-87FD-A5B69505BAEDQ35956533-D781C5F1-A06D-41C5-A1C0-4ACB501F2307Q36084675-C1467BC1-802E-4736-B041-872B0CC1C31EQ36167993-A4594B24-AD8F-4901-B990-614A3DD6D755Q36272971-4D6BE582-7EF8-44AF-87CB-9188ECA984B8Q36296560-B07A1867-8364-4C38-989A-75F177D8F708Q36306922-91ABCA65-217F-4241-AE41-A4FB65750540Q36367091-40265D12-A9E1-474F-AD0B-1CC09FC31C84Q36497877-3EB18E08-7F9B-4F1C-89E5-3C419AD42445Q36615539-81A67706-2F8E-4554-83E3-FACED96020A6Q36637886-85504BFE-B1F3-4D20-B5D9-2352A78B8A9BQ36717688-D9949802-1D0D-4313-9CE2-D96EF6B0576FQ36991782-D636D2C2-6D0A-4677-9EF1-21CCA5C1152FQ37083396-8600A4E4-5A13-4D43-8DF3-F121E30A91E2
P2860
Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Low 2012-13 influenza vaccine ...... c drift in circulating viruses
@ast
Low 2012-13 influenza vaccine ...... c drift in circulating viruses
@en
type
label
Low 2012-13 influenza vaccine ...... c drift in circulating viruses
@ast
Low 2012-13 influenza vaccine ...... c drift in circulating viruses
@en
prefLabel
Low 2012-13 influenza vaccine ...... c drift in circulating viruses
@ast
Low 2012-13 influenza vaccine ...... c drift in circulating viruses
@en
P2093
P2860
P50
P1433
P1476
Low 2012-13 influenza vaccine ...... c drift in circulating viruses
@en
P2093
Alireza Eshaghi
Anne-Luise Winter
Danuta M Skowronski
Kevin Fonseca
Martin Petric
Paul Van Caeseele
Suzana Sabaiduc
Trijntje L Kwindt
P2860
P304
P356
10.1371/JOURNAL.PONE.0092153
P407
P50
P577
2014-03-25T00:00:00Z